Edoxaban

Edoxaban (INN, codenamed DU-176b) is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. In animal studies, edoxaban is potent, selective for factor Xa and has good oral bioavailability, but it has not been approved for use in humans.

Several Phase II clinical trials have been conducted, for example for thromboprophylaxis after total hip replacement (phase III early results compare well to enoxaparin ), and for stroke prevention in patients with atrial fibrillation (phase III has completed enrollment ).